Can-Fite Biopharma surges as pancreatic cancer drug meets main goal in study

Can Fite Biopharma

04/03/2026 12:50

** U.S.-listed shares of Israel-based drug developer Can-Fite Biopharma CANF.TA more than double to $11.43 premarket

** Co says its investigational cancer drug, namodenoson, met the main goal of safety in a mid-stage study

** Can-Fite was testing the drug in previously-treated patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of cancer beginning in the pancreatic ducts

** Co says the drug was well-tolerated in heavily pre-treated patients; no new safety concerns were seen and side effects were consistent with prior studies

** Study included 20 patients whose cancer had worsened after previous treatments

** Co says it is still tracking survival, and about one‑third of patients were alive at the data cut-off

** CANF shares were down over 47% in 2025

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))